Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PORT for Low Risk Resected Stage IIIA(N2) NSCLC
NCT02977169Phase 2Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Nov 2016
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Disease-free survival at 3 years. Status: unknown.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02977169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02977169.